Which company offers more value? Array BioPharma Inc. (NASDAQ:ARRY), Mack-Cali Realty Corporation (NYSE:CLI)

Array BioPharma Inc. (NASDAQ:ARRY)

Array BioPharma Inc. (NASDAQ:ARRY) Performance Snapshot

Array BioPharma Inc. (NASDAQ:ARRY) Price Insight

Mack-Cali Realty Corporation (NYSE:CLI)

Mack-Cali Realty Corporation (NYSE:CLI), closed the last trading session at $14.04 with increase of $0.34 or 2.48 percent against the opening price of $13.7. The trading day volume of the company stands at 846271 shares while the average trading volume of Mack-Cali Realty Corporation (NYSE:CLI) is 747.09 Million over the course of 3 consecutive months. Which signifies a pretty good change over the time with its shares outstanding of 90.63 Million.

The price target of Mack-Cali Realty Corporation (NYSE:CLI) is currently set at 16.86 by the analysts. The stock is $-41.23 Below its 1-Year High which is $23.89. CLI hit its 1-Year low price of $12.26. The company is currently rated by analyst who are keeping a close eye on the stock as 3. Where 1 means Buy, 2.5 meaning Hold and 5 as Sell.

Performance Indicators of Mack-Cali Realty Corporation (NYSE:CLI)

The value of the stock increased by 1.96% during the previous week performance. Looking at the 1 month performance of Mack-Cali Realty Corporation (NYSE:CLI), the stock jumped 6.69%. While the 1 year performance shows a negative percentage of -35.15 and year to date performance stands at -39.3%.

Mack-Cali Realty Corporation (NYSE:CLI) Analytical Review

The stock needs to grow about $2.82 to reach its price target. In order to seek the stock’s directional movements, 20-Days, 50 Days and 200-Days moving averages are 8.08%, 2.39% and -18.85 percent respectively. The stock trades about 8.57 percent of its Float giving its total shares Outstanding are 90.63 Million. CLI gained about -22 percent in 6 months showing its Average True Range of 0.54. The company currently has a RSI and Beta of 59.24 and 0.93.

While talking about Mack-Cali Realty Corporation (NYSE:CLI) valuation ratios, the stock trades with a P/S and P/B of 3.97 and 0.91 which is significantly better and attractive as compared to its peers.